Form 4: Arcus Biosciences COO Jennifer Jarrett Sells Shares to Cover Tax Obligations

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold shares to cover tax withholding obligations related to vesting RSUs, as per the company's equity administration policy.

Summary

• Jennifer Jarrett, the Chief Operating Officer of Arcus Biosciences, Inc., sold shares of common stock on March 18, 2024, to cover tax withholding obligations.
• The sales were executed automatically under the company's equity administration policy implemented on January 15, 2021, and do not represent discretionary trades by Jarrett.
• A total of 12,153 shares were sold at a weighted average price of $17.84, with individual transactions ranging from $17.39 to $18.38.
• An additional 1,296 shares were sold at a weighted average price of $18.62, with individual transactions ranging from $18.44 to $18.92.
• Following these transactions, Jarrett directly owns 226,804 shares of Arcus Biosciences common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It doesn't indicate any significant positive or negative sentiment towards the company's prospects.

Positives

• The sales were part of a pre-existing equity administration policy, indicating a structured and transparent approach to executive compensation and tax obligations.

Industry Context

Executive stock sales to cover tax obligations are a common practice in publicly traded companies, especially following the vesting of restricted stock units (RSUs). This activity is closely monitored by investors for insights into executive sentiment and potential impact on stock price.

Comparison to Industry Standards

• Executive compensation practices, including RSU vesting and associated tax obligations, are standard across the biotechnology industry.
• Companies like Gilead Sciences, Amgen, and Regeneron also have similar equity administration policies to manage executive stock transactions.

Stakeholder Impact

• The stock sales may have a minor dilutive effect on existing shareholders, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates